| Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors CM Diaz, A Chiappori, L Aurisicchio, A Bagchi, J Clark, S Dubey, ... Journal of translational medicine 11, 1-13, 2013 | 94 | 2013 |
| Gray zone lymphoma with features intermediate between classical H odgkin lymphoma and diffuse large B‐cell lymphoma: C haracteristics, outcomes, and prognostication among a … AM Evens, JA Kanakry, LH Sehn, A Kritharis, T Feldman, A Kroll, ... American journal of hematology 90 (9), 778-783, 2015 | 91 | 2015 |
| Clinical updates for colon cancer care in 2022 JC Fabregas, B Ramnaraign, TJ George Clinical colorectal cancer 21 (3), 198-203, 2022 | 48 | 2022 |
| Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma IS Lossos, JC Fabregas, T Koru-Sengul, F Miao, D Goodman, AN Serafini, ... Leukemia & lymphoma 56 (6), 1750-1755, 2015 | 29 | 2015 |
| Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer JC Fabregas, A Loaiza-Bonilla, TN Talebi, S Warsch, G Fernandez, ... Expert review of anticancer therapy 13 (9), 1065-1072, 2013 | 13 | 2013 |
| Association of social determinants of health with late diagnosis and survival of patients with pancreatic cancer JC Fabregas, KE Riley, JM Brant, TJ George, EJ Orav, MB Lam Journal of Gastrointestinal Oncology 13 (3), 1204, 2022 | 10 | 2022 |
| Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2. TJ George, G Yothers, SA Jacobs, GG Finley, JL Wade, ... Journal of Clinical Oncology 40 (4_suppl), 99-99, 2022 | 8 | 2022 |
| National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer I Nassour, A Parrish, L Baptist, S Voskamp, K Handoo, S Rogers, ... HPB 25 (11), 1323-1328, 2023 | 4 | 2023 |
| Associations of total body fat mass and skeletal muscle index with all-cause and cancer-specific mortality in cancer survivors L Aduse-Poku, SD Karanth, M Wheeler, D Yang, C Washington, YR Hong, ... Cancers 15 (4), 1081, 2023 | 4 | 2023 |
| Impact of Medicaid expansion status and race on metastatic disease at diagnosis in patients with melanoma JC Fabregas, BT Carter, J Lutzky, WR Robinson, JM Brant Journal of racial and ethnic health disparities, 1-9, 2022 | 3 | 2022 |
| Prognostic value of CA 19-9 and carcinoembrionic antigen (CEA) in duodenal adenocarcinoma (DA): An institutional retrospective cohort study. E Altshuler, W King, R Richhart, K Hones, A Mathavan, A Mathavan, ... Journal of Clinical Oncology 40 (16_suppl), e16306-e16306, 2022 | 3 | 2022 |
| The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma P Prodduturvar, W Mneimneh, V Dal Zotto, S Akbar, L Grimm, P Rider, ... Oncotarget 12 (15), 1490, 2021 | 3 | 2021 |
| Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis M Ozer, SY Goksu, RY Lin, R Ayasun, D Kahramangil, SC Rogers, ... Journal of Hepatocellular Carcinoma, 1129-1141, 2023 | 1 | 2023 |
| An exploratory analysis of the intestinal microbiome in neoadjuvant chemotherapy for pancreatic cancer. S Rogers, R Thomas, B Ramnaraign, I Sahin, J Fabregas, K Russell, ... CANCER RESEARCH 82 (22), 81-82, 2022 | 1 | 2022 |
| Abstract B037: An exploratory analysis of the intestinal microbiome in neoadjuvant chemotherapy for pancreatic cancer S Rogers, R Thomas, B Ramnaraign, I Sahin, J Fabregas, K Russell, ... Cancer Research 82 (22_Supplement), B037-B037, 2022 | 1 | 2022 |
| Impact of radiotherapy for local control in T3 N0 rectal cancer managed with total mesorectal excision: A systematic review and meta-analysis. JC Fabregas, A Bang, M Tjong, M Kucharczyk Journal of Clinical Oncology 39 (15_suppl), 3604-3604, 2021 | 1 | 2021 |
| Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP … A Kritharis, JA Kanakry, LH Sehn, T Feldman, A Kroll, RD Gascoyne, ... Blood, The Journal of the American Society of Hematology 124 (21), 1703-1703, 2014 | 1 | 2014 |
| Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in … TJ George, SC Rogers, I Nassour, I Sahin, BH Ramnaraign, J Fabregas, ... Journal of Clinical Oncology 42 (3_suppl), 655-655, 2024 | | 2024 |
| A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma R Singhal, SC Rogers, JH Lee, B Ramnaraign, I Sahin, JC Fabregas, ... Future Oncology 19 (27), 1843-1853, 2023 | | 2023 |
| Associations of Fat Mass and Sarcopenia With All-Cause and Cancer-Specific Mortality in Cancer Survivors L Aduse-Poku, SD Karanth, M Wheeler, D Yang, C Washington, ... Cancer Epidemiology, Biomarkers & Prevention 32 (6), 859-859, 2023 | | 2023 |
Brian Hemendra Ramnaraign, MDUniversity of FloridaVerified email at medicine.ufl.edu
